Ann: Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine, page-2

ASX Announcement Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine Sydney, Australia, 6 December 2023: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce the European Patent Office has issued a notification of Intention to Grant a patent for its PD1-Vaxx cancer vaccine, a first-in-class programmed death-1 (PD1) vaccine, currently in clinical development for non-small cell lung cancer (NSCLC) and in 2024, colorectal cancer. The patent application, which covers the manufacturing and method of treatment, is expected to proceed to grant in late 2023 following completion of the grant formalities. Once granted, the patent will have a maximum term that will expire on 28 March 2038. The European Application (number 3600398) is titled “HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF”. Corresponding applications are pending in Canada, China, Hong Kong, India, South Korea, Brazil and Australia. The patent has previously received a Notice of Grant in the US and Japan. Imugene’s CEO and MD, Ms Leslie Chong, commented: “Receiving the notice that this European patent application will proceed to grant is an excellent milestone for the technology, and we are excited to continue developing the therapy to demonstrate the value of our PD1-Vaxx vaccine and to have a positive impact on the lives of many cancer patients.” Imugene’s PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung and colorectal cancer by interfering with PD-1/PD-L1 binding and interaction and produce an anti-cancer effect similar to Tecentiq®, Keytruda®, Opdivo® and the other immune checkpoint inhibitor monoclonal antibodies that are transforming the treatment of a range of cancers. For more information please contact: Leslie Chong Managing Director and Chief Executive Officer [email protected] Investor Enquiries [email protected] Media Enquiries Matt Wright [email protected] Follow us on Twitter @TeamImugene Like us on Facebook @Imugene Connect with us on LinkedIn @Imugene Limited View us on YouTube @Imugene Limited Join us on InvestorHub; IMU.investorhub.com About Imugene (ASX:IMU) Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market. Release authorised by the Managing Director and Chief Executive Officer